IJPR  artciles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 1.55 (2012 - 2016). 

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
PIPPHARMACON & IJPR 2018

PIPPHARMACON & IJPR 2018

Click to download
 

Article Detail

Label
Label
Semisynthetic colon-specific prodrugs of boswellic acid for inflammatory bowel disease: Design, Pharmacokinetic and Pharmacodynamic studies

Author: AJINKYA SARKATE, SUNEELA S. DHANESHWAR
Abstract: Mutual amide prodrugs of ?-boswellic acid (BBA) with L-glutamine and L-cysteine were synthesized for the management of inflammatory bowel disease. Conjugation with amino acids improved the hydrophilicity of BBA (log P: 4.9 to5.3) to enable efficient delivery to colon. Prodrugs were stable in 0.05M HCl buffer (pH 1.2) and stomach homogenates. Negligible hydrolysis was observed in phosphate buffer and intestinal homogenates. Prodrugs were substantially cleaved to release BBA in homogenates of colon (59-63%) and rat fecal matter (49-52%). Site-specifically enhanced bioavailability of BBA could be achieved in colon and prodrug of BBA with L-glutamine (BG) demonstrated a significant ameliorating effect on the inflamed colonic mucosa in TNBS-induced colitis in Wistar rats without the SLZ-associated adversities on stomach, liver and pancreas. BG could be developed further as a safer colon-specific prodrug for potential application in the management of IBD.
Keyword: Inflammatory bowel disease, Complementary and alternative medicine, Boswellic acid, colon-targeting, mutual prodrugs, TNBS-induced colitis
Download: Request For Article
 












USER LOGIN


Username
Password
Login | Register
AICTE INTERNATIONAL CONFERENCE

AICTE Sponsored International Conference on Challenges, Opportunities and Newer Directions of Pharmacovigilance and Clinical Research in India

Download Brochure


For More Detail Visit www.pippharmacon.org
News & Events

CiteScore 2016 -  0.09

SJR 2016 - 0.111

SNIP 2016 - 0.055

Impact Factor for five years is 1.55 (2012 - 2016)
Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477
Impact Factor for five years is 1.3 (2010 - 2014)